TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00588692

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: SphygmoCor
Description: The SphygmoCor, a hand-held tonometer will assess central blood pressure noninvasively. This pencil-like device is applied over the radial artery, and uses a validated mathematical transformation to derive central aortic pressure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SphygmoCor
Description: The SphygmoCor, a hand-held tonometer will assess central blood pressure noninvasively. This pencil-like device is applied over the radial artery, and uses a validated mathematical transformation to derive central aortic pressure.
Study: NCT01571960

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for MVA62B:
Description: Administered as a 1-mL IM injection into the deltoid

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for MVA62B:
Description: Administered as a 1-mL IM injection into the deltoid
Study: NCT02799563

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coach, Preselected number of cases

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coach, Self-selected number of cases

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No coach, Preselected number of cases

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No coach, Self-selected number of cases
Study: NCT02651870

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan 16mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan 16mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan 16mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 10mg
Study: NCT02486692

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AboutFace Website
Description: AboutFace is an informational website that utilizes digital storytelling to describe PTSD symptoms and different treatments for PTSD.
Study: NCT01906242

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: water

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sodium hypochlorite

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sodium bicarbonate

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine
Study: NCT00480090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Initially given at 1g/m2 bid for 2 days every 3 weeks over 2 hours. The dose will be escalated: level 1 - 1.25g/m2, level 2, 1.5g/m2.
Study: NCT00877318

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCAD information system
Description: Cardiac rehabilitation at home by telemedicine
Study: NCT03276650

Intervention type: OTHER
Intervention: data collection
Description: biological, administrative, clinical, outcome date
Study: NCT02995759

Intervention type: OTHER
Intervention: Seizure Action Plan
Description: The action plan will be electronically formatted in the EMR. After electronic creation, the primary neurologist and patient/caregiver will create a patient-specific plan.
Study: NCT00484029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Carbon Dioxide
Description: Nasal Carbon Dioxide

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Air
Description: Air (Medical Grade)
Study: NCT02466464

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microporous Polysaccharide Hemospheres
Description: Two grams of Arista powder will be placed into the nose followed by four minutes of pressure and a moustache dressing.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microporous Polysaccharide Hemospheres
Description: Two grams of Arista powder will be placed into the nose followed by four minutes of pressure and a moustache dressing.
Study: NCT04956471

Intervention type: OTHER
Intervention: interview
Description: A sample method: convenience sampling, selecting A 3 armour hospital between September 2019 and January 2020 neurology hospital patients with swallowing disorder after stroke, about 15 cases.
Study: NCT02466464

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Tampon
Description: 8 cm of Merocel dressing will be placed into one or both sides of your nose for the next three to five days and will then be removed by the physician.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Tampon
Description: 8 cm of Merocel dressing will be placed into one or both sides of your nose for the next three to five days and will then be removed by the physician.
Study: NCT02668965

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrauterine hCG (pregnyl)
Study: NCT00057291

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Responsive caregiving
Description: Responsive caregiving consisted of operational circumstances and training of caregivers.
Study: NCT00129441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Merck L-830982
Description: The initial dose of L-830982 was 3.0 mg twice daily (b.i.d.) the dosage increased to 5.0 mg b.i.d. at the end of week 1 and 8.0 mg b.i.d. at the end of week 2, which was continued for the remaining 2 weeks of the trial. Medications were dispensed weekly in blister packs by the hospital pharmacy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Medications were dispensed weekly in blister packs by the hospital pharmacy, using the same number of pills as those on active drug.
Study: NCT01716806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.8 mg/kg every 3 weeks by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.8 mg/kg every 3 weeks by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.8 mg/kg every 3 weeks by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.8 mg/kg every 3 weeks by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.8 mg/kg every 3 weeks by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.8 mg/kg every 3 weeks by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine
Description: 70 mg/m\^2 by IV infusion on Days 1 and 2 of 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacarbazine
Description: 375 mg/m\^2 every 3 weeks by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: 3 mg/kg every 3 weeks by IV infusion
Study: NCT01893112

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unity Workshop
Description: The intervention is based on other stigma reduction programs that are being used internationally (HIV Stigma Toolkit developed by the International Center for Research on Women and trigger videos developed by International Training \& Education Center for health).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Breast Cancer Screening
Study: NCT00508950

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Large volume blood draw
Description: Large volume blood draw
Study: NCT00938353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beclomethasone dipropionate suspension for nebulisation 800 mcg/2 ml
Description: Single dose 1600 mcg/4 ml
Study: NCT05653102

Intervention type: DEVICE
Intervention: Truliant Total Knee System
Description: Total Knee Arthroplasty using Exactech's Truliant® branded components are compatible with Optetrak branded components.
Study: NCT00938353

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution for nebulisation 2 ml
Description: single dose: 4 ml
Study: NCT02155192

Intervention type: DRUG
Intervention: No Intervention

Intervention type: DRUG
Intervention: No Intervention

Intervention type: DRUG
Intervention: No Intervention

Intervention type: DRUG
Intervention: No Intervention
Study: NCT00667563

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
Description: Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA analysis
Description: Weeks 0, 2, 10, 26, and 52.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Screening, week 36, and week 52.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cytology specimen collection procedure
Description: Screening, week 36, and week 52.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: colposcopic biopsy
Description: Screening, week 36, and week 52.
Study: NCT05653102

Intervention type: DEVICE
Intervention: Truliant Total Knee System
Description: Total Knee Arthroplasty using Exactech's Truliant® branded components are compatible with Optetrak branded components.

Intervention type: DEVICE
Intervention: Truliant Total Knee System
Description: Total Knee Arthroplasty using Exactech's Truliant® branded components are compatible with Optetrak branded components.
Study: NCT03370744

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological scale
Description: Neuropsychological scale, including mini-mental state examination (MMSE), Montreal cognitive assessment (MoCA), clinical dementia rating scales (CDR) and so on

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological scale
Description: Neuropsychological scale, including mini-mental state examination (MMSE), Montreal cognitive assessment (MoCA), clinical dementia rating scales (CDR) and so on
Study: NCT03159936

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tofacitinib citrate
Description: 10 mg daily by mouth
Study: NCT00356447

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol/DRSP (Angeliq, BAY86-4891)
Description: Drospirenone (DRSP) 2mg and Estradiol 1mg. One cycle consists of 28 days. One tablet daily for 28 days given for a total of 4 cycles. Oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same administration.
Study: NCT00692380

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fractionated radiation therapy followed by chemotherapy
Description: Increasing doses of radiation therapy
Study: NCT03370744

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological scale
Description: Neuropsychological scale, including mini-mental state examination (MMSE), Montreal cognitive assessment (MoCA), clinical dementia rating scales (CDR) and so on

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological scale
Description: Neuropsychological scale, including mini-mental state examination (MMSE), Montreal cognitive assessment (MoCA), clinical dementia rating scales (CDR) and so on

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological scale
Description: Neuropsychological scale, including mini-mental state examination (MMSE), Montreal cognitive assessment (MoCA), clinical dementia rating scales (CDR) and so on
Study: NCT04348526

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corticision
Description: Surgical intervention is going to be used in the interdental areas between the lower anterior teeth to accelerate tooth movement. Three incisions are going to be made

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional orthodontic treatment
Description: No surgical intervention will be used, just normal orthodontic sequence of procedures.
Study: NCT04088669

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based Pulmonary Rehabilitation
Description: Patients will admit a home-based pulmonary rehabilitation program for 8 weeks, with a minimum of 3 days per week and one session of this is under the supervision of a physiotherapist. The pulmonary rehabilitation program includes stretching exercises, strengthening exercises for upper and lower extremities, breathing exercises and aerobic exercises (walking). All of these exercises will be equipped with equipment that the patients can easily provide at home. In addition, patients will be provided with a pedometer and exercise diary.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education and Recommendations
Description: The control group will be given a training session on the course of the disease and the correct inhaler use and will be given booklets on breathing exercises, aerobic exercises (walking) and physical activity recommendations for a minimum of 2-3 days per week for 8 weeks. Patients will be given a pedometer and exercise diary.
Study: NCT02581683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Given via adductor canal block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Given via adductor canal block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Given via adductor canal block

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham adductor canal block
Study: NCT02191488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid
Study: NCT01950299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg
Description: Anakinra 100 mg starting immediately and then every 24 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg
Description: Anakinra 100 mg starting immediately and then every 24 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg
Description: Anakinra 100 mg starting 12 hours after first dose and then every 24 hours (so that Anakinra is given every 12 hours)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo 0.67 ml injections twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 0.67 ml injections twice daily
Study: NCT03946059

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTBS then cTBS
Description: repetitive transcranial magnetic stimulation applied with intermittent theta-burst stimulation protocol applied in week 1 and continuous theta-burst stimulation protocol applied in week 2.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cTBS then iTBS
Description: repetitive transcranial magnetic stimulation applied with continuous theta-burst stimulation protocol applied in week 1 and intermittent theta-burst stimulation protocol applied in week 2.
Study: NCT01960101

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LactoXeros

Intervention type: DEVICE
Group type: OTHER
Intervention: Aequasyal
Study: NCT03001947

Intervention type: OTHER
Intervention: No intervention
Description: Registration of all IgAN patients in the First Affiliated Hospital of Sun Yat-sen University and other hospitals which have signed the contract in China.
Study: NCT04567940

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ENRED@TE: Behavioural multicomponent intervention
Description: Information and awareness activities; activities for the acquisition of skills; activities that help the elderly to attend spaces for leisure, participation and maintenance and/or improvement of their personal relationships.
Study: NCT01811732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delafloxacin
Description: Delafloxacin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Vancomycin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aztreonam
Description: Aztreonam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03808233

Intervention type: OTHER
Intervention: ACTIVE mini
Description: the ACTIVE-mini, is a non-invasive method of recording movement in an infant using a KINECT camera system. This camera is positioned over a resting infant and measures natural movement over a two minute time period.

Intervention type: OTHER
Intervention: ACTIVE mini
Description: the ACTIVE-mini, is a non-invasive method of recording movement in an infant using a KINECT camera system. This camera is positioned over a resting infant and measures natural movement over a two minute time period.
Study: NCT02392026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole Gel
Description: Metronidazole Vaginal Gel 1.3% administered via applicator
Study: NCT03280407

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Radio-chemotherapy with 50.4 Gy in 28 fractions to tumor and regional lymph nodes concomitantly with capecitabine 825 mg/m2 b.i.d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen (oxaliplatin/leucovorin/5FU)
Description: Six cycles: Oxaliplatin 85 mg/m2 day 1, leucovorin 400 mg/m2 day 1, 5FU 400 mg/m2 bolus day 1 and 5FU 2400 mg/ m2 over 46-48 hours day 1-3, repeated every two weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAPOX (oxaliplatin/capecitabine)
Description: Four cycles: Oxaliplatin 130 mg/m2 day 1 and capecitabine 1000 mg/m2 b.i.d. days 1-14, repeated every 3 weeks.
Study: NCT01105520

Intervention type: PROCEDURE
Intervention: Diagnostic
Description: SCIM Spinal Cord Independence Measure ASIA scale American Spinal Injury Association
Study: NCT04784130

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity
Description: Respondents will complete activity logs (step count, using pedometer) and surveys (two items from the Summary of Diabetes Self-care activities measure) for physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Respondents will complete activity logs (step count, using pedometer) and surveys (two items from the Summary of Diabetes Self-care activities measure) for physical activity.
Study: NCT02951520

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: new technique for lower limb nerve blocks using a single skin puncture (SOFT block)
Description: The patients will be in supine position. The block needle will be inserted at the inguinal crease (medial to the femoral vein) and advanced towards the femoral nerve, then redirected towards the obturator nerve (deep to the pectineus muscle). Lastly, it will be redirected posteriorly towards the sciatic nerve (deep to the quadratus femoris muscle). A ropivacaine-lidocaine-epinephrine mixture will be used to block these nerves. The block success rate (painless surgery), performance time and patient discomfort will be recorded.
Study: NCT04792619

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bobath Approach
Description: The patients in both groups were treated with the exercise program according to the Bobath concept was planned taking the functional needs of the survivors into account, including stretching and facilitation of latissimus dorsi muscle, facilitation of abdominal muscles, placing exercises, training of lumbar spine stabilizers, functional reach of shoulder in different directions. Five sessions of about an hour each were provided to the patients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bobath Approach
Description: The patients in both groups were treated with the exercise program according to the Bobath concept was planned taking the functional needs of the survivors into account, including stretching and facilitation of latissimus dorsi muscle, facilitation of abdominal muscles, placing exercises, training of lumbar spine stabilizers, functional reach of shoulder in different directions. Five sessions of about an hour each were provided to the patients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isometric scapular exercises
Description: Isometric scapular exercises were performed to the patients included to the study group in a sitting position and at 900 of the shoulder flexion and 900 of the shoulder abduction. The patients were exercised by a physiotherapist using isometric contraction in protraction and retraction by a physiotherapist. Isometric contractions lasted 5 seconds and each exercise was repeated 2x15 times. One minute rest period was given between sets
Study: NCT04784130

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Respondents will complete activity logs (step count, using pedometer) and surveys (two items from the Summary of Diabetes Self-care activities measure) for physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Adherence
Description: Respondents will provide information on their medication adherence using a survey (questionnaire - MMAS-8).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Modification
Description: Respondents will complete food logs and surveys (three items from the Summary of Diabetes Self-care activities measure) for dietary intake.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Modification
Description: Respondents will complete food logs and surveys (three items from the Summary of Diabetes Self-care activities measure) for dietary intake.
Study: NCT01249417

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: I.M. (in the muscle) injection on day 1 of a single treatment cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: I.M. (in the muscle) injection on day 1 of a single treatment cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: I.M. injection on day 1 of a single treatment cycle.
Study: NCT02760719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nebulized 3% hypertonic solution
Description: already described
Study: NCT01480388

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/JNJ-39758979 (300 mg/d)
Description: Form = tablet, route = oral adminstration placebo once daily from Week 0 to Week 24 followed by JNJ-39758979 300 mg once daily from Week 24 to Week 48.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39758979 (10 mg)
Description: Form = tablet, route = oral adminstration once daily up to 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39758979 (30 mg)
Description: Form = tablet, route = oral adminstration once daily up to 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39758979 (100 mg)
Description: Form = tablet, route = oral adminstration once daily up to 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39758979 (300 mg)
Description: Form = tablet, route = oral adminstration once daily for 48 weeks